Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL19236131 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL13524298 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL177909 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22503340 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25052982 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL12127070 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25446250 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL21465719 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL23134940 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22667521 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 84646 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12599571-B2 | Method for preparing polydopamine nanomotor using urease, and use of same | POSTECH Research and Business Development Foundation (KR) | 2026-04-14 | — | — | US | claimed |
| US-12594344-B2 | Production of exosomes and uses thereof | CHINA MEDICAL UNIVERSITY (TW) | 2026-04-07 | — | — | US | claimed |
| US-12583865-B2 | Biologically active taxane analogs and methods of treatment by oral administration | TAPESTRY PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4701667-A1 | TROP2 BINDERS AND CONJUGATES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-03-04 | — | — | EP | claimed |
| US-20260048014-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY OF PROTEIN FRAGMENTS | SIGNABLOK INC (US) | 2026-02-19 | — | — | US | claimed |
| EP-0617018-A1 | Beta-lactams, methods for the preparation of taxanes, and sidechain-bearing taxanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-09-28 | — | — | EP | claimed |
| WO-1994014787-A1 | NOVEL SIDECHAIN-BEARING TAXANES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1994012172-A1 | METHODS OF KILLING PROTOZOAL PARASITES | THOMAS JEFFERSON UNIVERSITY (US) | 1994-06-09 | — | — | WO | claimed |
| WO-1994010995-A1 | ANTITUMOUR COMPOSITIONS CONTAINING TAXANE DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1994-05-26 | — | — | WO | claimed |
| CN-1085552-A | 10-deacetylation baccatin III manufacture method | RHONE POULENC RORER SA (FR) | 1994-04-20 | — | — | CN | claimed |
| CN-1085551-A | 10-deacetylation baccatin III manufacture method | RHONE POULENC RORER SA (FR) | 1994-04-20 | — | — | CN | claimed |
| WO-1994007882-A1 | METHOD OF OBTAINING 10-DEACETYLBACCATINE III | RHONE-POULENC RORER S.A. (FR) | 1994-04-14 | — | — | WO | claimed |
| WO-1994007881-A1 | METHOD OF OBTAINING 10-DEACETYLBACCATINE III | RHONE-POULENC RORER S.A. (FR) | 1994-04-14 | — | — | WO | claimed |
| WO-1993023014-A1 | CHEMOTHERAPEUTIC DRUG COMBINATIONS | MARTIN DANIEL S (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0568821-A1 | Callus cell induction and the preparation of taxanes | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | claimed |